Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 4(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04257487Phase 3Recruiting

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Role: lead

NCT03803579Completed

Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)

Role: lead

NCT03678506Phase 4Terminated

Apixaban for Extended Anticoagulation (APIDULCIS)

Role: lead

NCT02219984Recruiting

START-Register: Survey on Anticoagulated Patients Register

Role: collaborator

NCT04646993Completed

WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?

Role: lead

NCT04454554Completed

Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)

Role: lead

All 6 trials loaded